Sphere Bio

Executive Summary

Sphere Bio is a UK-based biotechnology company that specializes in single-cell analysis and isolation technologies, leveraging proprietary picodroplet microfluidics. Since its founding in 2017, the company has developed automated platforms, assay kits, and consumables that accelerate workflows in antibody discovery, cell line development, and cell therapy. Its core value proposition lies in enabling researchers to find and isolate high-value cells with speed, ease, and monoclonality assurance. By addressing critical bottlenecks in biologics development and cell therapy manufacturing, Sphere Bio positions itself as a key enabler for biopharmaceutical R&D. The company's technology has the potential to reduce timelines and improve efficiency in the discovery of therapeutic antibodies and the development of cell-based therapies. As a private company with no disclosed funding or revenue figures, Sphere Bio operates in a competitive landscape that includes established players like 10x Genomics and Berkeley Lights. However, its focus on picodroplet microfluidics and monoclonality assurance differentiates its offerings. The company is well-positioned to capture market share as demand for high-throughput single-cell analysis grows. While specific financial and commercial milestones are not publicly available, Sphere Bio's technology foundation and market timing suggest promising growth potential. The company's ability to execute on product development and forge strategic partnerships will be key to its success.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation single-cell isolation platform70% success
• Q2 2027Strategic partnership with a top-20 pharma for antibody discovery50% success
• Q1 2027Series B funding round to support commercialization80% success